Creative Planning Acquires 2,260 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Creative Planning grew its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 64.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,744 shares of the company’s stock after purchasing an additional 2,260 shares during the period. Creative Planning’s holdings in Krystal Biotech were worth $1,046,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its stake in Krystal Biotech by 54.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock worth $117,189,000 after purchasing an additional 231,255 shares during the last quarter. Principal Financial Group Inc. grew its holdings in shares of Krystal Biotech by 1,972.0% during the second quarter. Principal Financial Group Inc. now owns 123,469 shares of the company’s stock valued at $22,674,000 after buying an additional 117,510 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Krystal Biotech by 115.7% during the second quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company’s stock valued at $35,583,000 after buying an additional 103,928 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Krystal Biotech by 167.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 158,425 shares of the company’s stock valued at $28,189,000 after buying an additional 99,101 shares during the last quarter. Finally, Capital World Investors purchased a new stake in shares of Krystal Biotech during the first quarter valued at approximately $17,285,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Chardan Capital increased their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a report on Monday, August 5th. Stifel Nicolaus increased their price target on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Citigroup reiterated a “neutral” rating and set a $204.00 price target (up previously from $195.00) on shares of Krystal Biotech in a report on Tuesday, August 6th. Finally, HC Wainwright increased their price objective on shares of Krystal Biotech from $200.00 to $221.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Krystal Biotech has an average rating of “Buy” and an average target price of $196.75.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the transaction, the insider now directly owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 14.10% of the company’s stock.

Krystal Biotech Trading Down 1.7 %

KRYS opened at $172.53 on Friday. Krystal Biotech, Inc. has a 1-year low of $93.95 and a 1-year high of $219.34. The company has a market capitalization of $4.93 billion, a PE ratio of 92.26 and a beta of 0.82. The firm’s 50 day simple moving average is $183.38 and its two-hundred day simple moving average is $179.88.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, August 5th. The company reported $0.53 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.03. Krystal Biotech had a net margin of 63.73% and a return on equity of 1.99%. The business had revenue of $70.28 million for the quarter, compared to the consensus estimate of $65.27 million. During the same period last year, the firm earned ($1.25) earnings per share. The company’s quarterly revenue was up 70283900.0% on a year-over-year basis. Equities analysts forecast that Krystal Biotech, Inc. will post 3.13 earnings per share for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).